California life science companies and research institutions seeking to commercialize new stem cell-based drugs may soon be able to borrow from the state in addition to applying for grants to pay for their research.
 
The California Institute for Regenerative Medicine, the state agency created in 2004 by voter-approved Proposition 71 to issue grants in support of public and private stem-cell research, has begun crafting terms for a loan program to help companies and institutions carry out that work.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.